Occam Places CEO for RadioPharm Start-Up
ARTBIO was founded by Roy Larsen, PhD inventor of the technology behind the breakthrough radiotherapeutic cancer drug, Xofigo. Occam placed Emanuele Ostuni, PhD the former head of Novartis Oncology's cell and gene therapy unit in Europe, as CEO.
The global start-up with offices in Oslo, London, Basel, and Boston just emerged from stealth with a robust pipeline and $23M from an international syndicate of investors, including F-Prime Capital and Omega Funds.
ARTBIO's board includes Ted Love, CEO of Global Blood Therapeutics until its $5.4B acquisition by Pfizer, and Susanne Schaffert, former President of Novartis Oncology. ARTBIO's lead asset in prostate cancer entered the clinic and will be developed quickly alongside other internal pipeline programs.
Occam Global is a leading executive search and advisory partner for entrepreneurs, investors, and corporations targeting exceptional goals across the life sciences, deep tech, and venture capital sectors worldwide. Since 2012, Occam has collaborated with top founders, CEOs, and investors across the tech industry to provide high-performing leaders who fuel growth. From stealth startups to public markets, we recruit senior executives, advise on organizational strategies, and invest alongside visionary teams to build innovative companies. Occam’s success is rooted in our proven ability to attract outstanding business and scientific leaders, seamless access to rare talent, and a strong commitment to results guided by high ethics and enlightened aggression. Whether you’re launching, leading, or investing, we are here to support growth through the power of talent.